Statistiche di base
| LEI | 549300ZEL6TXZS6F5F95 |
| CIK | 313143 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Haemonetics Corporation
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 7, 2025 |
Exhibit 10.1 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT This PERFORMANCE SHARE UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (as amend |
|
| August 7, 2025 |
Haemonetics Reports First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guid |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as s |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement x Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri |
|
| May 27, 2025 |
Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2024 to December 31, 2024 This is the Conflict Minerals Report (“CMR”) of Haemonetics Corporation (“Haemonetics,” “we,” “us,” or “our”) for the reporting period from January 1, 2024 to December 31, 2024 pursuant to Rule 13p-1 (“Rule 13p-1”) promulgated under the Securities Exchange Act of 1934 |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 29, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact n |
|
| May 21, 2025 |
Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Advanced Cooling Therapy, LLC Delaware Arryx, Inc. Nevada Cardiva Medical, Inc. Delaware Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics Asia Incorporated Delaware Hae |
|
| May 8, 2025 |
Haemonetics Reports Fourth Quarter and Fiscal 2025 Results; Provides Fiscal 2026 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Global Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Fourth Quarter and Fiscal 2025 Results; Provides Fisca |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissio |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| March 3, 2025 |
Exhibit 99.1 Investor Contacts: Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Senior Director-Global Communications (781) 356-9776 [email protected] Haemonetics Announces Executive Leadership Updates Frank Chan joins H |
|
| February 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| February 6, 2025 |
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2025 Results; Updates Fiscal 2025 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2025 Results; Updates F |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant |
|
| January 14, 2025 |
Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A Exhibit 99.1 Investor Contacts: Media Contact: Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 [email protected] Josh Gitelson, Sr. Director-Global Communications (781) 356-9776 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A BOSTON, J |
|
| January 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Com |
|
| December 3, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| December 3, 2024 |
Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A Exhibit 99.1 Investor Contacts: Media Contact: Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 [email protected] Josh Gitelson, Sr. Director-Global Communications (781) 356-9776 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A BOSTON, D |
|
| November 12, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Haemonetics Corporation is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k |
|
| November 7, 2024 |
Haemonetics Reports Second Quarter and First Half Fiscal 2025 Results; Updates Fiscal 2025 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Second Quarter and First Half Fiscal 2025 Results; Updates Fi |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Co |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as s |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| August 8, 2024 |
Haemonetics Reports First Quarter Fiscal 2025 Results; Reaffirms Fiscal 2025 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports First Quarter Fiscal 2025 Results; Reaffirms Fiscal 2025 Guid |
|
| July 30, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commi |
|
| July 25, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement x Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| May 29, 2024 |
Form of Confirmation of Base Call Option Transaction. Exhibit 10.1 [Dealer] [] [] Attention: [] Telephone No.: [] Facsimile No.: [] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Michelle Basil, General Counsel Telephone No.: Email: From: Re: Base Call Option Transaction Date: May 22, 2024 Dear Ladies and Gentlemen: The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions |
|
| May 29, 2024 |
Form of Confirmation of Additional Call Option Transaction. Exhibit 10.2 [Dealer] [] [] Attention: [] Telephone No.: [] Facsimile No.: [] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Michelle Basil, General Counsel Telephone No.: Email: From: Re: Additional Call Option Transaction Date: May 23, 2024 Dear Ladies and Gentlemen: The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and condi |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of |
|
| May 29, 2024 |
Exhibit 4.1 Haemonetics Corporation and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of May 28, 2024 2.50% Convertible Senior Notes due 2029 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 12 Section 1.03. Rules of Construction 13 Article 2. The Notes 14 Section 2.01. Form, Dati |
|
| May 28, 2024 |
Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2023 to December 31, 2023 This is the Conflict Minerals Report (“CMR”) of Haemonetics Corporation (“Haemonetics,” “we,” “us,” or “our”) for the reporting period from January 1, 2023 to December 31, 2023 pursuant to Rule 13p-1 (“Rule 13p-1”) promulgated under the Securities Exchange Act of 1934 |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri |
|
| May 23, 2024 |
Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury David Trenk, Manager-Investor Relations (781) 356-9763 (203) 733-4987 [email protected] [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senio |
|
| May 23, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of |
|
| May 21, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of |
|
| May 21, 2024 |
Haemonetics Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury David Trenk, Manager-Investor Relations (781) 356-9763 (203) 733-4987 [email protected] [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Announces Proposed Convertible Senior Notes Offering BOSTON, MA, M |
|
| May 20, 2024 |
ADDENDA NO 2 Adresse des lieux loues 750, boulevard du Parc Technologique Québec (Québec) G1P 4S3 Page 1 s ADDENDA NO 2 Adresse des lieux loues 750, boulevard du Parc Technologique Québec (Québec) G1P 4S3 ENTRE: 1405 PTQM S. |
|
| May 20, 2024 |
Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Advanced Cooling Therapy, Inc. Delaware Arryx, Inc. Nevada Cardiva Medical, Inc. Delaware Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics Asia Incorporated Delaware Ha |
|
| May 20, 2024 |
HAEMONETICS CORPORATION COMPENSATION RECOVERY POLICY Exhibit 97.1 HAEMONETICS CORPORATION COMPENSATION RECOVERY POLICY Haemonetics Corporation, a Massachusetts corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in acco |
|
| May 20, 2024 |
[ADDENDA NO 1] Adresse des lieux loues 750, boulevard du Parc Technologique Québec (Québec) G1P 4S3 Page 1 [ADDENDA NO 1] Adresse des lieux loues 750, boulevard du Parc Technologique Québec (Québec) G1P 4S3 ENTRE : 1405 PTQM S. |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact n |
|
| May 20, 2024 |
Page 1 BAIL ENTRE 1405 PTQM (SEC) (ci-après le « Bailleur ») ET Opsens Inc. (ci-après le « Locataire ») Adresse des Lieux loues : 750,.boulevard du Parc Technologique Québec (Québec) G1P 4S3 Échéance du terme du bail ; 30 septembre·2025 Page 2 TABLE DES MATIÈRES 1. INTENTION DES PARTIES 4 2. IMMEUBLE 4 3. LIEUX LOUES 5 4. DURÉE DE LOCATION 5 5. USAGE 5 6. OCCUPATION 5 7. NON RELOCALISATION 5 8. LO |
|
| May 20, 2024 |
HAEMONETICS CORPORATION SECURITIES TRADING POLICY Exhibit 19.1 HAEMONETICS CORPORATION SECURITIES TRADING POLICY 1.Purpose This Securities Trading Policy (this “Policy”) sets forth the guidelines of Haemonetics Corporation and its subsidiaries (collectively, “Haemonetics”) regarding compliance with U.S. and foreign securities laws and regulations relating to trading in Haemonetics and third-party securities. The purpose of this Policy is to promo |
|
| May 9, 2024 |
Haemonetics Reports Fourth Quarter and Fiscal 2024 Results; Provides Fiscal 2025 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Fourth Quarter and Fiscal 2024 Results; Provides Fiscal 2025 Guidan |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissio |
|
| May 1, 2024 |
Exhibit 10.1 EXECUTION VERSION SECOND AMENDED AND RESTATED CREDIT AGREEMENT dated as of April 30, 2024 among HAEMONETICS CORPORATION The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., BofA SECURITIES, INC., CITIBANK, N.A., CITIZENS BANK, N.A., PNC CAPITAL MARKETS LLC, TRUIST SECURITIES, INC., U.S. BANK NATIONAL ASSOCIATION and WELLS FARGO SEC |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| April 1, 2024 |
Haemonetics Corporation Completes Acquisition of Attune Medical Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Corporation Completes Acquisition of Attune Medical BOSTON, April |
|
| April 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| March 5, 2024 |
Haemonetics Announces Definitive Agreement to Acquire Attune Medical Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Announces Definitive Agreement to Acquire Attune Medical BOSTON, M |
|
| March 5, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| February 13, 2024 |
HAE / Haemonetics Corporation / Neuberger Berman Group LLC Passive Investment SC 13G/A 1 formsc13ga-02132024080223.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* HAEMONETICS CORP (Name of Issuer) Common (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 13, 2024 |
HAE / Haemonetics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01063-haemoneticscorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 14)* Name of issuer: Haemonetics Corp Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate |
|
| February 9, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant |
|
| February 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| February 8, 2024 |
SIXTH AMENDMENT TO LEASE AGREEMENT CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL, IS THE TYPE THAT HAEMONETICS CORPORATION TREATS AS CONFIDENTIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| February 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 8, 2024 |
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2024 Results; Updates Fiscal 2024 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2024 Results; Updates Fiscal |
|
| February 8, 2024 |
CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL, IS THE TYPE THAT HAEMONETICS CORPORATION TREATS AS CONFIDENTIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| December 12, 2023 |
Haemonetics Corporation Completes Acquisition of OpSens Inc. Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Corporation Completes Acquisition of OpSens Inc. Boston, MA, Decem |
|
| December 12, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Com |
|
| November 2, 2023 |
Haemonetics Reports Second Quarter and First Half Fiscal 2024 Results; Updates Fiscal 2024 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Second Quarter and First Half Fiscal 2024 Results; Updates Fiscal 2 |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| October 12, 2023 |
Exhibit 2.1 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL, IS THE TYPE THAT HAEMONETICS CORPORATION TREATS AS CONFIDENTIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. HAEMONETICS CORPORATION and 9500-7704 QUÉBEC INC. and OPSENS INC. ARRANGEMENT AGREEMENT October 10, 2023 11633442v2 TABLE OF CONTENTS Article 1 INTERPRETA |
|
| October 12, 2023 |
Exhibit 10.1 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL, IS THE TYPE THAT HAEMONETICS CORPORATION TREATS AS CONFIDENTIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. VOTING SUPPORT AGREEMENT THIS AGREEMENT is made as of October 10, 2023 BETWEEN: [NAME], an individual resident in [●] (the “Shareholder”) - and - 9500-77 |
|
| October 12, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of |
|
| October 10, 2023 |
Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc. |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that each of the undersigned, being a director or officer, or both, of Haemonetics Corporation (the “Company”), constitutes and appoints Christopher A. Simon, President and Chief Executive Officer, and Michelle L. Basil, Executive Vice President and General Counsel, and each of them, his or her true and lawful attorneys-in-fact and |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Haemonetics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Proposed Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| August 8, 2023 |
Exhibit 10.3 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT This NONQUALIFIED STOCK OPTION AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (as |
|
| August 8, 2023 |
Exhibit 10.1 Haemonetics Corporation Worldwide Employee Bonus Plan (As Amended and Restated Effective May 13, 2023) 1.Background and Purpose. 1.1Purpose. The purpose of the Haemonetics Corporation Worldwide Employee Bonus Plan (the “Plan”) is to provide incentive compensation to those eligible employees with significant responsibility for the growth, profitability and success of the Company’s busi |
|
| August 8, 2023 |
Exhibit 10.2 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (as amended |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 1, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as sp |
|
| August 8, 2023 |
Exhibit 10.4 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT This PERFORMANCE SHARE UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (as amend |
|
| August 8, 2023 |
Haemonetics Reports First Quarter Fiscal 2024 Results; Updates Fiscal 2024 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports First Quarter Fiscal 2024 Results; Updates Fiscal 2024 Guidance Bos |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| August 7, 2023 |
HAEMONETICS CORPORATION AMENDED AND RESTATED 2019 LONG-TERM INCENTIVE COMPENSATION PLAN Exhibit 10.1 HAEMONETICS CORPORATION AMENDED AND RESTATED 2019 LONG-TERM INCENTIVE COMPENSATION PLAN Effective as of the Effective Date (as defined below), the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan is hereby amended and restated (as amended and restated, the “Plan”). The purpose of the Plan is to provide employees of Haemonetics Corporation (the “Company”) and its subs |
|
| August 7, 2023 |
Diane M. Bryant Joins Haemonetics' Board of Directors Exhibit 99.1 Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Diane M. Bryant Joins Haemonetics' Board of Directors BOSTON, Aug. 7, 2023 - H |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| June 16, 2023 |
DEFA14A 1 a2023additionalproxymateri.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri |
|
| May 30, 2023 |
Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2022 to December 31, 2022 This is the Conflict Minerals Report (“CMR”) of Haemonetics Corporation (“Haemonetics,” “we,” “us,” or “our”) for the reporting period from January 1, 2022 to December 31, 2022 pursuant to Rule 13p-1 (“Rule 13p-1”) promulgated under the Securities Exchange Act of 1934 |
|
| May 22, 2023 |
Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Arryx, Inc. Nevada Cardiva Medical, Inc. Delaware Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics Asia Incorporated Delaware Haemonetics Asia UK Ltd. United Kingdom Ha |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 1, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact na |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi |
|
| May 11, 2023 |
Haemonetics Reports Fourth Quarter and Fiscal 2023 Results; Provides Fiscal 2024 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Fourth Quarter and Fiscal 2023 Results; Provides Fiscal 2024 Guidan |
|
| February 13, 2023 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 10, 2023 |
HAE / Haemonetics Corporation / Neuberger Berman Group LLC - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Haemonetics Corp (Name of Issuer) Common (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 9, 2023 |
HAE / Haemonetics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Haemonetics Corp. Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 7, 2023 |
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2023 Results; Updates Fiscal 2023 Guidance Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2023 Results; Updates Fiscal |
|
| February 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| November 8, 2022 |
AMENDMENT II SHELTER PLAN SERVICE AGREEMENT DATED JUNE 10, 2014 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 1, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as |
|
| November 7, 2022 |
Haemonetics Reports Second Quarter and First Half Fiscal 2023 Results; Updates Fiscal 2023 Guidance Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports Second Quarter and First Half Fiscal 2023 Results; Updates Fiscal 2023 Guidance Boston, MA, November 7, 2022 - Haemonetics Corporation (NYSE: HAE) repo |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| October 11, 2022 |
HAE / Haemonetics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0011-haemoneticscorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Haemonetics Corp. Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: September 30, 2022 Check the appropriate box to designate |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 2, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as sp |
|
| August 10, 2022 |
SUPPLEMENTAL RELEASE OF CLAIMS Exhibit 10.2 June 14, 2022 Michelle Basil c/o Haemonetics Corporation 125 Summer Street Boston, MA 02110 RE: Executive Vice President and General Counsel Retention and Transition Agreement Dear Michelle: This Retention and Transition Agreement (this ?Agreement?) sets forth the understanding between you and Haemonetics Corporation (the ?Company?) regarding your continued employment as Executive Vic |
|
| August 10, 2022 |
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports First Quarter Fiscal 2023 Results; Updates Fiscal 2023 Guidance; Announces New $300 Million Share Repurchase Authorization Boston, MA, August 10, 2022 |
|
| August 10, 2022 |
CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| August 1, 2022 |
EXECUTION VERSION AMENDED AND RESTATED CREDIT AGREEMENT dated as of July 26, 2022 among HAEMONETICS CORPORATION The Lenders Party Hereto and JPMORGAN CHASE BANK, N. |
|
| August 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material under ?240. |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under ?240. |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| May 26, 2022 |
EX-1.01 2 a2021conflictmineralsrepor.htm EX-1.01 Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2021 to December 31, 2021 This is the Conflict Minerals Report (“CMR”) of Haemonetics Corporation (“Haemonetics,” “we,” “us,” or “our”) for the reporting period from January 1, 2021 to December 31, 2021 pursuant to Rule 13p-1 (“Rule 13p-1”) prom |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri |
|
| May 25, 2022 |
Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Arryx, Inc. Nevada Cardiva Medical, Inc. Delaware Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics (UK) Limited United Kingdom Haemonetics Asia Incorporated Delaware Ha |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 2, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact na |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi |
|
| May 10, 2022 |
Haemonetics Reports Fourth Quarter and Fiscal 2022 Results; Provides Fiscal 2023 Guidance Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports Fourth Quarter and Fiscal 2022 Results; Provides Fiscal 2023 Guidance Boston, MA, May 10, 2022 - Haemonetics Corporation (NYSE: HAE) reported financial |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) March 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| March 21, 2022 |
Haemonetics Appoints James D’Arecca Chief Financial Officer Exhibit 99.1 Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Appoints James D?Arecca Chief Financial Officer Boston, MA, March 21, 2022 - Haemonetics Corporation (NYSE: HAE) today announced that James C. D?Arecca will join the |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Com |
|
| February 14, 2022 |
HAE / Haemonetics Corporation / Neuberger Berman Group LLC - NONE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Haemonetics Corp (Name of Issuer) Common (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 10, 2022 |
HAE / Haemonetics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Haemonetics Corp. Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) January 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 8, 2022 |
FOURTEENTH AMENDMENT TO AGREEMENT OF LEASE DATED THIS 11th DAY OF NOVEMBER, 2021 BY AND BETWEEN CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| February 8, 2022 |
SUPPLEMENTAL RELEASE OF CLAIMS Exhibit 10.2 November 8, 2021 William P. Burke Address on file with the Company RE: CFO Retention and Transition Agreement Dear Bill: This Retention and Transition Agreement (this ?Agreement?) sets forth the understanding between you and Haemonetics Corporation (the ?Company?) regarding your continued employment as Chief Financial Officer of the Company and your planned retirement from the Company |
|
| February 8, 2022 |
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2022 Results; Updates Fiscal 2022 Guidance Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2022 Results; Updates Fiscal 2022 Guidance Boston, MA, February 8, 2022 - Haemonetics Corporation (NYSE: HAE) reported financial |
|
| February 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2022 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commi |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 1, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 2, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commi |
|
| November 9, 2021 |
Haemonetics Announces CFO William P. Burke’s Retirement for June 2022 Exhibit 99.2 Investor Contact Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact Josh Gitelson, Director-Global Communications (781) 356-9776 [email protected] Haemonetics Announces CFO William P. Burke?s Retirement for June 2022 BOSTON, MA, November 9, 2021 ? Haemonetics Corporation (NYSE: HAE), a global medical technology company focus |
|
| November 9, 2021 |
Haemonetics Reports Second Quarter and 1st Half Fiscal 2022 Results; Updates Fiscal 2022 Guidance Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports Second Quarter and 1st Half Fiscal 2022 Results; Updates Fiscal 2022 Guidance Boston, MA, November 9, 2021 - Haemonetics Corporation (NYSE: HAE) reported financial re |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 3, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as sp |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| August 11, 2021 |
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 [email protected] [email protected] Haemonetics Reports First Quarter Fiscal 2022 Results; Increases Guidance for Vascular Closure Revenue and Affirms All Other Fiscal 2022 Guidance; Expands Operational Excellence Program |
|
| August 9, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material under ?240. |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under ?240. |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) May 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| May 28, 2021 |
Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2020 to December 31, 2020 This is the Conflict Mineral Report (?CMR?) of Haemonetics Corporation (?Haemonetics,? ?we,? ?us,? or ?our?) for the reporting period from January 1, 2020 to December 31, 2020 pursuant to Rule 13p-1 (?Rule 13p-1?) promulgated under the Securities Exchange Act of 1934, |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 3, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact na |
|
| May 26, 2021 |
Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Arryx, Inc. Nevada Cardiva Medical, Inc. Delaware Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics (UK) Limited United Kingdom Haemonetics Asia Incorporated Delaware Ha |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi |
|
| May 13, 2021 |
Haemonetics Reports Fourth Quarter and Fiscal 2021 Results; Provides Fiscal 2022 Guidance Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports Fourth Quarter and Fiscal 2021 Results; Provides Fiscal 2022 Guidance Boston, MA, May 13, 2021 - Haemonetics Corporation (NYSE: HAE) reported financial results for its |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi |
|
| April 19, 2021 |
HAEMONETICS PROVIDES UPDATE ON U.S. PLASMA BUSINESS Exhibit 99.1 Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, Vice President-Communications (781) 348-7263 [email protected] HAEMONETICS PROVIDES UPDATE ON U.S. PLASMA BUSINESS BOSTON, MA, April 19, 2021 - Haemonetics Corporation (NYSE: HAE) (?Haemonetics? or the ?Company?), a global medical techno |
|
| April 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction o |
|
| March 16, 2021 |
Form of Confirmation of Additional Call Option Transaction. Exhibit 10.1 [] [] [] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Telephone No.: Email: From: Re: Additional Call Option Transaction Date: March 12, 2021 Dear Ladies and Gentlemen: The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the call option transaction entered into between [] (?Dealer?) and Haemonetic |
|
| March 5, 2021 |
Form of Confirmation of Call Option Transaction. Exhibit 10.1 [] [] [] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Telephone No.: Email: From: Re: Base Call Option Transaction Date: March 2, 2021 Dear Ladies and Gentlemen: The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the call option transaction entered into between [] (?Dealer?) and Haemonetics Corpo |
|
| March 5, 2021 |
Exhibit 4.1 Haemonetics Corporation and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of March 5, 2021 0.00% Convertible Senior Notes due 2026 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 13 Article 2. The Notes 14 Section 2.01. Form, Dating and Denominations |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of |
|
| March 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of |
|
| March 3, 2021 |
Haemonetics Prices $435.0 Million Convertible Senior Notes Offering Exhibit 99.1 Haemonetics Prices $435.0 Million Convertible Senior Notes Offering BOSTON, March 2, 2021?Haemonetics Corporation (?Haemonetics?) (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2026 (the ?notes?) in a private offering (the ?offering?) to qualified institutional buyers pursuant to Rule 144A under |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Commission File Number: 001-14041 Massachusetts 04-2882273 (State or other jurisdiction of |
|
| March 1, 2021 |
Exhibit 10.1 AMENDMENT NO. 1 Dated as of March 1, 2021 to CREDIT AGREEMENT Dated as of June 15, 2018 THIS AMENDMENT NO. 1 (this ?Amendment?) is made as of March 1, 2021 by and among HAEMONETICS CORPORATION, a Massachusetts corporation (the ?Company?), the financial institutions listed on the signature pages hereof as ?Term A-2 Lenders?, the existing Lenders (immediately prior to the effectiveness |
|
| March 1, 2021 |
Haemonetics Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 Haemonetics Announces Proposed Convertible Senior Notes Offering BOSTON, March 1, 2021—Haemonetics Corporation (“Haemonetics”) (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $425,000,000 aggregate principal amount of Convertible Senior Notes due 2026 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers purs |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 12, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Haemonetics Corp (Name of Issuer) Common (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Haemonetics Corp. Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 2, 2021 |
TWELFTH AMENDMENT TO AGREEMENT OF LEASE DATED THIS 22nd DAY OF MAY, 2020 BY AND BETWEEN CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| February 2, 2021 |
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2021 Results Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2021 Results Boston, MA, February 2, 2021 - Haemonetics Corporation (NYSE: HAE) reported financial results for its third quarter a |
|
| February 2, 2021 |
THIRTEENTH AMENDMENT TO AGREEMENT OF LEASE DATED THIS 21st DAY OF DECEMBER, 2020 BY AND BETWEEN CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| February 2, 2021 |
FIRST AMENDMENT TO LEASE AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (“Amendment”) is entered into this 1st day of October, 2020, by and between CLINTON COMMERCE III, LLC, a Pennsylvania limited liability company ("Landlord"), and HAEMONETICS CORPORATION, a Massachusetts corporation ("Tenant"). WITNESSETH: WHEREAS, Landlord and Tenant entered into that certain Industrial Lease A |
|
| February 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commi |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 26, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant |
|
| February 2, 2021 |
CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| January 20, 2021 |
HAEMONETICS TO ACQUIRE CARDIVA MEDICAL, INC. TO EXPAND HOSPITAL PORTFOLIO Exhibit 99.1 Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, Vice President-Communications (781) 348-7263 [email protected] HAEMONETICS TO ACQUIRE CARDIVA MEDICAL, INC. TO EXPAND HOSPITAL PORTFOLIO •Enhances penetration into the large and growing interventional cardiology and electrophysiology mar |
|
| January 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2021 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| November 10, 2020 |
HAE / Haemonetics Corp. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Haemonetics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) October 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 26, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant |
|
| November 4, 2020 |
Haemonetics Reports Second Quarter and 1st Half Fiscal 2021 Results Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports Second Quarter and 1st Half Fiscal 2021 Results Boston, MA, November 4, 2020 - Haemonetics Corporation (NYSE: HAE) reported financial results for its second quarter and |
|
| September 18, 2020 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Co |
|
| August 4, 2020 |
Haemonetics Reports First Quarter Fiscal 2021 Results Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports First Quarter Fiscal 2021 Results Boston, MA, August 4, 2020 - Haemonetics Corporation (NYSE: HAE) reported financial results for its first quarter of fiscal 2021, whic |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of in |
|
| August 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 27, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as s |
|
| August 4, 2020 |
CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| August 4, 2020 |
Haemonetics Reports First Quarter Fiscal 2021 Results Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports First Quarter Fiscal 2021 Results Boston, MA, August 4, 2020 - Haemonetics Corporation (NYSE: HAE) reported financial results for its first quarter of fiscal 2021, whic |
|
| July 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| July 24, 2020 |
HAEMONETICS ANNOUNCES SALE OF INLOG HOLDINGS FRANCE SAS TO ABÉNEX CAPITAL Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, VP- Global Communications (781) 348-7263 [email protected] FOR IMMEDIATE RELEASE HAEMONETICS ANNOUNCES SALE OF INLOG HOLDINGS FRANCE SAS TO ABÉNEX CAPITAL BOSTON, MA, July 24, 2020 - Haemonetics Corporation (NYSE: HAE), a global medical technology co |
|
| July 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi |
|
| July 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| June 30, 2020 |
ARTICLE IV Place of Shareholders’ Meetings Exhibit 3.2 The amendments to the Company’s By-Laws effective June 29, 2020 are set forth below. Text stricken through indicates deletions, and text that is underlined indicates additions. ARTICLE IV Place of Shareholders’ Meetings All meetings of the shareholders shall be held either or both (a) at the principal office of the Corporation in Massachusetts, unless a different place within Massachus |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| June 30, 2020 |
HAEMONETICS CORPORATION ARTICLE I Articles of Organization Exhibit 3.1 As amended through June 29, 2020 BY-LAWS of HAEMONETICS CORPORATION ARTICLE I Articles of Organization The name and purposes of the Corporation shall be as set forth in the Articles of Organization. These By-Laws, the powers of the Corporation and of its Directors and shareholders, and all matters concerning the conduct and regulation of the business of the Corporation shall be subject |
|
| June 30, 2020 |
HAEMONETICS ANNOUNCES 2020 ANNUAL MEETING OF SHAREHOLDERS WILL BE CONDUCTED IN VIRTUAL FORMAT Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, VP-Global Communications (781) 348-7263 [email protected] HAEMONETICS ANNOUNCES 2020 ANNUAL MEETING OF SHAREHOLDERS WILL BE CONDUCTED IN VIRTUAL FORMAT BOSTON, MA, June 30, 2020 - Haemonetics Corporation (NYSE: HAE) |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement x Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| June 11, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commiss |
|
| June 11, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, VP- Global Communications (781) 348-7263 [email protected] HAEMONETICS ANNOUNCES BLOOD FILTER SUPPLY AGREEMENT AND SALE OF PUERTO RICO-BASED MANUFACTURING OPERATIONS TO GVS S.p.A BOSTON, MA, June 3, 2020 - Haemoneti |
|
| June 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| June 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement x Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 125 Summer Street, Boston, MA 02110 (Address of pri |
|
| May 29, 2020 |
Exhibit 1.01 Conflict Minerals Report of Haemonetics Corporation For the reporting period from January 1, 2019 to December 31, 2019 This is the Conflict Minerals Report (“CMR”) of Haemonetics Corporation (“Haemonetics,” “we,” “us,” or “our”) for the reporting period from January 1, 2019 to December 31, 2019 pursuant to Rule 13p-1 (“Rule 13p-1”) promulgated under the Securities Exchange Act of 1934 |
|
| May 28, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissi |
|
| May 28, 2020 |
HAEMONETICS ANNOUNCES SALE OF U.S. BLOOD DONOR MANAGEMENT SOFTWARE SOLUTION ASSETS TO THE GPI GROUP Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 [email protected] Media Contact: Carla Burigatto, VP-Communications (781) 348-7263 [email protected] HAEMONETICS ANNOUNCES SALE OF U.S. BLOOD DONOR MANAGEMENT SOFTWARE SOLUTION ASSETS TO THE GPI GROUP BOSTON, MA, May 28, 2020 - Haemonetics Corporation (NYSE: HAE), |
|
| May 20, 2020 |
EXHIBIT 4B DESCRIPTION OF REGISTRANT’S COMMON STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 28, 2020, Haemonetics Corporation (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): shares of Common Stock, $0. |
|
| May 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 28, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact n |
|
| May 20, 2020 |
Subsidiary of Haemonetics Corporation Exhibit 21.1 - Subsidiaries of the Company Subsidiary of Haemonetics Corporation Jurisdiction of Incorporation or Organization 5D Information Management, Inc. Delaware Arryx, Inc. Nevada Enicor GmbH Germany Global Med Technologies, Inc. Colorado Haemonetics (Hong Kong) Limited Hong Kong Haemonetics (UK) Limited United Kingdom Haemonetics Asia Incorporated Delaware Haemonetics Asia UK Ltd. United K |
|
| May 5, 2020 |
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports 4th Quarter and Fiscal 2020 Results; Provides Update on Business Continuity and Impacts from COVID-19 Boston, MA, May 5, 2020 - Haemonetics Corporation (NYSE: HAE) repo |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commissio |
|
| April 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| April 17, 2020 |
Michael Coyle Joins Haemonetics Board of Directors For Immediate Release Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 olga. |
|
| April 9, 2020 |
HAE / Haemonetics Corp. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) March 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| March 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Com |
|
| February 14, 2020 |
HAE / Haemonetics Corp. / Neuberger Berman Group LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Haemonetics Corp (Name of Issuer) Common (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 12, 2020 |
HAE / Haemonetics Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Haemonetics Corp Title of Class of Securities: Common Stock CUSIP Number: 405024100 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| February 4, 2020 |
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports 3rd Quarter and Year-to-Date Fiscal 2020 Results; Reaffirms Revenue Guidance and Raises All Other Guidance for Fiscal 2020 Boston, MA, February 4, 2020 - Haemonetics Co |
|
| February 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant |
|
| February 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| January 27, 2020 |
HAE / Haemonetics Corp. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Haemonetics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 405024100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| January 14, 2020 |
FOR IMMEDIATE RELEASE Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 olga. |
|
| January 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| November 1, 2019 |
Exhibit 99.1 Earnings Release FY20 Q2 Investor Contact Media Contact Olga Guyette, Sr. Mgr.-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 [email protected] [email protected] Haemonetics Reports 2nd Quarter and 1st Half Fiscal 2020 Results; Raises Fiscal 2020 Adjusted Operating Margin and Adjusted EPS Guidance Braintree, MA, November 1, |
|
| November 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2019 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Comm |
|
| November 1, 2019 |
LEASE ARTICLE 1 Reference Information EXHIBIT 10.6 LEASE ARTICLE 1 Reference Information 1.1 Reference Information. Reference in this Lease to any of the following shall have the meaning set forth below: Effective Date: August 26, 2019. Lot: Premises: The parcel of land known as 400 Wood Road, Braintree, Massachusetts, more particularly described on Exhibit A attached hereto. The building situated on the Lot (the “Building”). Landlord |
|
| November 1, 2019 |
EXHIBIT 10.4 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT This NONQUALIFIED STOCK OPTION AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (th |
|
| November 1, 2019 |
EXHIBIT 10.2 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (the “Plan” |
|
| November 1, 2019 |
EXHIBIT 10.5 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT This PERFORMANCE SHARE UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (the “Pla |
|
| November 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant |
|
| November 1, 2019 |
EXHIBIT 10.3 HAEMONETICS CORPORATION 2019 LONG-TERM INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of [●] (the “Date of Grant”), is delivered by Haemonetics Corporation (the “Company”) to [●] (the “Participant”). RECITALS The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (the “Plan” |
|
| August 30, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2019 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commi |
|
| August 6, 2019 |
Exhibit 99.1 Earnings Release FY20 Q1 Investor Contacts Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 [email protected] [email protected] Olga Vlasova, Sr. Mgr.-Investor Relations (781) 356-9763 [email protected] Haemonetics Reports 1st Quarter Fiscal 2020 Results, Updates Fiscal 2020 Earnings Gu |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 001-14041 04-2882273 (State or other jurisdiction of incorporation) (Commis |
|
| August 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 29, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as s |
|
| July 30, 2019 |
Post-Effective Amendment to Form S-8 As filed with the Securities and Exchange Commission on July 30, 2019 Registration No. |
|
| July 30, 2019 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that each of the undersigned, being a director or officer, or both, of Haemonetics Corporation (the “Company”), constitutes and appoints Christopher A. Simon, President and Chief Executive Officer, and Michelle L. Basil, Executive Vice President, General Counsel, and each of them, his or her true and lawful attorneys-in-fact and age |
|
| July 30, 2019 |
HAE / Haemonetics Corp. S-8 - - S-8 As filed with the Securities and Exchange Commission on July 30, 2019 Registration No. |
